



THERAPEUTIC POTENTIAL OF LICHEN PARMELIA PERLATA AGAINST DUAL DRUG-
RESISTANT HELICOBACTER PYLORI ISOLATES 
Original Article 
 
VALENTINA GEHLOT1, SHWETA MAHANT1, POOJA VIJAYRAGHWAN1, KUNAL DAS2,3, SHANU HODA1,  
RAJASHREE DAS1* 
1Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India, 2Max Superspeciality Hospital, Patparganj, New Delhi, 
India, 3
 Received: 13 Oct 2015 Revised and Accepted: 18 Nov 2015 
Yasodha Superspeciality Hospital, Ghaziabad, Uttar Pradesh, India 
Email: rajashreepatra79@yahoo.co.in  
ABSTRACT 
Objective: H. pylori have acquired resistance to the commonly used antibiotics due to their use in many anaerobic and parasitic infections leading to 
treatment failure of various gastroduodenal diseases associated with H. pylori infection. Our aim was to test the efficacy of Parmelia perlata which is 
traditionally used for the treatment of dysentery, diarrhea, and dyspepsia against antibiotic resistant gastric pathogen H. pylori. 
Methods: The antimicrobial activity of an ethanolic and methanolic extract of P. perlata against drug-resistant H. pylori isolates from North India in 
vitro was carried out by determining the Minimum inhibition concentration (MIC) using disk diffusion method and microdilution method. 
Results: Two H. pylori isolates were included in this study. One was resistant to both metronidazole (MIC of 64 µg/ml) and clarithromycin (MIC of 4 
µg/ml) and another one was resistant to metronidazole only having a MIC of 64 µg/ml. Methanolic and ethanolic extract of P. perlata showed its 
effectiveness in inhibiting drug resistant H. pylori isolates with maximum inhibition at 500 × 103
Conclusion: Prevalence of metronidazole resistant ranges between 50–90% in developing countries including India with the emergence of dual-
drug resistance was reported in many studies. This study suggests that P. perlata used commonly as a spice in food has a potential for the treatment 
of drug-resistant H. pylori infection in a safe and effective manner. 
 µg/ml concentration of P. perlata.  
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INTRODUCTION 
Helicobacter pylori are a gastric pathogen and are associated with 
several gastroduodenal diseases such as chronic gastritis, peptic 
ulcer, and gastric cancer [1-3]. More than one-half of world’s 
population carries the H. pylori infection and in India its prevalence 
exceeds 90% of the population. Eradication of H. pylori from infected 
individuals remains the best choice for an effective treatment of H. 
pylori-associated diseases. Triple therapy, consisting of the 
combination of two antibiotics and a proton pump inhibitor, gives a 
high eradication rate [4]. The common antibiotics used against H. 
pylori are Metronidazole, Clarithromycin, Furazolidone, Amoxicillin, 
and Tetracycline. Misuse of antibacterial agents in general 
population for various respiratory and anaerobic infections have 
resulted in the emergence of antibiotic-resistant strains which is the 
prime cause of treatment failure apart from potential side effects [5, 
6]. Metronidazole and clarithromycin are the most commonly used 
antibiotics in H. pylori treatment. Prevalence of resistance against 
metronidazole has been found to be high in many studies [4, 7, 8]. 
 The emergence of dual and multidrug resistance has also increased 
significantly in many countries and has become a major obstacle in 
eradicating the H. pylori infection [8-11]. In view of the incomplete 
cure achieved with a conventional triple therapy comprising 
metronidazole and clarithromycin, there is an urgent need to 
develop new treatment strategies for H. pylori infection. 
Therefore, in such a scenario, there is a crucial need to find new 
antimicrobial agents. Unlike synthetic drugs, bioactive natural 
products are beneficial for the humans without causing unwanted 
side-effects. In this search lichens are the new bioactive 
preparations of natural origin. Lichens produce secondary 
metabolites the “lichen substances”, which comprise depsides, 
depsidones, dibenzofurans, xanthones and terpene derivatives. 
Lichens and their metabolites have multiple biological activities: 
antiviral, antibiotic, antitumor, allergenic, plant growth inhibitory, 
anti-herbivore, ecological roles and enzyme inhibitory [12, 13]. 
Parmelia perlata, commonly called as the stone flower is generally 
used as a spice to enhance the taste and flavor of the foods. P. perlata 
is lichen that is widely distributed in the hilly areas of the Indian 
subcontinent. In ancient folklore it has been used in cosmetic and has 
been reported to have medicinal value. It was used for the treatment of 
dysentery, wound healing, diarrhea, and dyspepsia [14, 15].  
Studies have been conducted using different extracts of P. perlata 
against various bacterial and fungal pathogens. It contains many 
compounds like tridecyl myristate, 3-ketooleanane, icosan-1ol etc. 
[16]. Recent studies have shown that methanolic extract of Lichen 
possesses anti-microbial potential [17]. Our aim is to study the 
antimicrobial activity of the methanolic and ethanolic extracts of the 
lichen P. perlata against dual-drug resistant H. pylori in safe and 
effective manner. 
MATERIALS AND METHODS 
Collection of sample 
P. perlata was collected from the local Indian market and 
authenticated in the Botany Department of Amity University. The 
plant was properly washed under running tap water and then rinsed 
in distilled water. Then it was air dried in shade and grinded into 
powder using mortar and pestle. 
Preparation of extracts 
In order to obtain the extract, about 100 gms of P. perlata were 
crushed with mortar and pestle and sieved. The dried powder was 
then extracted with 400 ml n-Hexane, chloroform, Methanol and 
Ethanol consecutively for 72 h/solvent under constant stirring. The 
extract was then filtered and dried under pressure and resuspended 
in the solvent. Methanolic and ethanolic extract of P. perlata were 
used in the present study. 
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H. pylori strains and culture 
Patients suffering from various gastroduodenal diseases were 
included in this study. H. pylori strains were isolated from antral 
biopsies collected from patients and were identified on the basis of 
colony appearance, gram staining, and positive reactions in 
biochemical tests (catalase, urease, and oxidase). H. pylori strain was 
isolated and cultured on brain heart infusion (BHI) agar (Difco 
Laboratories, Detroit, MI) supplemented with 5% horse serum 
(Invitrogen, NY), 0.4% Isovitale X (Becton Dickinson, MD), 
trimethoprim (5µg/ml), vancomycin (8µg/ml), and polymixin B 
(10µg/ml). The plates were incubated at 37 oC in a microaerophilic 
atmosphere (5% O2, 10% CO2, 85% N2) (Double gas incubator, Hera 
cell 150i) for 3 to 6 d. Stock cultures were maintained until use at–
70 oC in Brain heart infusion broth with 20% glycerol. 
Suspension preparation 
The bacterial suspension was prepared by the direct colony method 
[18]. The colonies were taken directly from the plate and were 
suspended in 5 mL of sterile 0.85% phosphate buffer saline (PBS). 
The turbidity of the initial suspension was adjusted by comparing 
with McFarland’s standard number 2 (3 µl of which contains about 1 
×108
(a) Disk diffusion method 
 colony forming units (CFU)/ml) [19]. 
Determination of antimicrobial susceptibility and resistance 
H. pylori cells growing exponentially on antibiotic free BHI agar were 
suspended in Phosphate buffered saline (PBS) buffer, a series of 10-
fold dilutions of these cell suspensions was prepared, and 10 µl of 
each dilution was spotted on freshly prepared BHI agar containing 
various concentration of different antibiotics (µg/ml) viz. 
Metronidazole (0.2, 0.5, 1.5, 3, 8, 16, 32, 64), Clarithromycin (0.125, 
025, 1, 2), Furazolidone (0.2, 0.5, 1, 2), Amoxicillin (0.125, 0.25, 1, 2) 
and Tetracycline (1, 2, 3, 4). 
Minimum inhibitory concentration (MIC) 
After 72 h incubation under microaerophilic conditions, the minimal 
inhibitory concentration was recorded as the lowest concentration 
that inhibited visible growth of organisms. Minimal inhibitory 
concentration (MIC) for different antibiotics was defined as 
Metronidazole (>8 µg/ml) [20], Clarithromycin (>0.5 µg/ml) [20], 
Amoxicillin (>0.12 µg/ml) [20], Tetracycline (>1 µg/ml) [20] and 
Furazolidone (>2 µg/ml) [7]. 
Anti- H. pylori activity assay of P. perlata extracts 
Sterile Whatman paper disks (6 mm in diameter) were loaded with 
different concentration of methanolic and ethanolic extracts of P. 
perlata and placed on the inoculated plates with 3 ×109 colony 
forming unit (CFU) of H. pylori. The plates were kept under 
observation for 2 d at 37o C under microaerophilic conditions (5% 
O2,  10% CO2 and 85% N2
(b) Micro-dilution method 
). All experiments were performed in 
triplicates. Pure methanol and ethanol were used as a negative 
control and amoxicillin were used as positive control. 
Minimum inhibitory concentration (MIC) was also determined by 
microdilution method. The 96-well plate was prepared by 
dispensing 80 µl of BHI broth into first well. A 20 µl from the stock 
solution of lichen extract (5 × 104 µg/ml) was added to the first well. 
Then, five-fold serial dilution was performed till 8th well. The 
obtained concentration range was from 4000 µg/ml to 0.05 µg/ml. 
To each well 150 µl of the diluted bacterial cells were added to give 
final concentration of 3 × 109 CFU/ml. The inoculated plates were 
incubated at 37 ° C for 2 d at microaerophilic conditions. MIC90
Rapid urease test (RUT) was also done for visualization of microbial 
growth. The basis of the test is the ability of H. pylori to secrete 
urease enzyme which hydrolyzes the urea to ammonia and carbon 
dioxide and raises the pH of the medium from yellow (H. pylori 
negative) to pink color (H. pylori positive). MIC was defined as the 
lowest concentration of extract sample that prevented RUT medium 
color change from yellow to pink (fig. 2). 
RESULTS  
Two clinical H. pylori isolates were included in this study isolated 
from a patient suffering from Non-erosive reflux disease (NERD) and 
Gastroesophageal reflux disease (GERD). The MIC of H. pylori isolate 
for metronidazole, clarithromycin, furazolidone, amoxicillin and 
tetracycline were determined by agar dilution method. Out of the 
two strains one strain was found resistant to metronidazole only 
having MIC of 64 µg/ml but sensitive to all drugs namely 
clarithromycin, furazolidone, amoxicillin, and tetracycline having 
MIC of 0.125 µg/ml, 0.2 µg/ml, 0.125 µg/ml and 1 µg/ml 
respectively and another strain was resistant to both clarithromycin 
and metronidazole having MIC of 4 µg/ml and 64 µg/ml respectively 
but sensitive to furazolidone, amoxicillin, and tetracycline with MIC 
of 2 µg/ml, 0.125 µg/ml and 1 µg/ml respectively. 
Antimicrobial activity 
Disc diffusion method 
 was 
defined as the lowest concentration of extract sample that inhibited 
the 90 % of H. pylori cells when to compare to control i.e. H. pylori 
cells without extract sample. Reading was noted on Elisa reader 
(Erba Lisa Scan II). 
Different concentration of methanolic and ethanolic extract of P. 
perlata was loaded onto the disc and was air dried. 100 µl of the 
suspended H. pylori strain in PBS having Mac Farland 2 (3× 109 
CFU/ml) was spread plated onto BHI medium. The disc loaded with 
the extracts was placed upside down in the H. pylori plates (fig. 1). 
After 72 h of incubation, we found that the methanolic and ethanolic 
extract of P. perlata has anti-H. pylori activity. MIC of P. perlata was < 
50 × 103 µg/ml (table 1). Among the different concentration tested 
for both the extracts 500 × 103
  
 µg/ml displayed maximum inhibition 
against the drug resistant H. pylori strain. The diameter of the zone 




Fig. 1: Disk diffusion method: Antimicrobial activity of P. perlata extracts against metronidazole-resistant H. pylori strain (a) Methanolic 
extract of P. perlata. (b) Ethanolic extract of P. perlata. 
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Table 1: Antimicrobial activity of methanolic and ethanolic extract of Parmelia perlata against drug-resistant H. pylori strains 
Strain 
No. 





Ethanolic extracts of P. perlata 
(Disk diffusion method) 
MIC90 Methanolic extracts of P. perlata 
(Disk diffusion method) 

























50 × 10 8.0±0.1 3 800 µg/ml 50 × 10 10.0±0.0 3 32 µg/ml 
250 × 10 10.0±0.5 3 250 × 10 12.0±0.1 3 
500 × 10 14.0±0.2 3 50 × 10 15.0±0.0 3 




50 × 10 8.0±0.0 3 800 µg/ml 50 × 10 8.0±0.1 3 32 µg/ml 
250 × 10 11.0±0.1 3 250 × 10 13.0±0.0 3 
500 × 10 13.0±0.5 3 500× 10 15.0±0.5 3 
a
 
= mean±SD (n = 3), MTZ = Metronidazole, CLR = Clarithromycin, GERD = Gastro-esophageal reflux disease, NERD = Non-erosive reflux disease 
Microdilution method 
The antimicrobial activity of lichen extract was evaluated by 
microdilution method. The MIC was determined in two drugs 
resistant clinical H. pylori isolates. MIC values ranged between 4000 
µg/ml to 0.05 µg/ml (fig. 2). MIC90
 
 values of a methanolic and 
ethanolic extract of P. perlata were 0.1 µg/ml and 31.3 µg/ml 
respectively against H. pylori isolate resistant to both metronidazole 
and clarithromycin. 
 
Fig. 2: Micro-dilution method: lane 1 to 8 shows the Five-fold 
serial dilution of lichen extract from lane 1 to lane 8 with a 
constant cell count of H. pylori. Lane 9 shows media control 
without cells. Lane 10 shows the cell control without lichen 
extract. Lane 11 shows extract control without cells. Lane 12 
shows the control in which the lichen extract dissolved with 
cells. MIC90
 
 was observed at lane 4 and Lane 2 for methanolic 
and ethanolic extract of P. perlata respectively 
DISCUSSION 
Due to increasing use of antibiotics over the last two decades, H. 
pylori have acquired antimicrobial resistance and are the main cause 
of treatment failure. Previous studies have shown that the 
prevalence of resistance to metronidazole in different parts of India 
were Delhi (37.5%) [21], Chandigarh (38.2%) [21], Lucknow (68%) 
[21], Gangetic belt of North India (100%)[22]Hyderabad (100%) 
[21] Chennai (88.2%) [21], Kolkata (85%) [7] and Gujarat (83.8%) 
[23]. High prevalence of metronidazole-resistant H. pylori has also 
been reported from other developing countries (China, 77.8%; 
Bangladesh, 77.8%; Mexico, 76.3%) [24, 25]. In India, the high 
prevalence of multidrug-resistant strain was observed in 
(Multicentric study in India, 43.2%; Gujarat, 85%)[21, 23]. Our 
recent studies have shown the prevalence of Dual and multidrug 
resistance in 26.5% (18/68) and 8.9% (6/68) of cases in India [8]. 
The high prevalence of dual drug resistant H. pylori isolates has 
prompted us to look into the natural products which can be effective 
against H. pylori.  
Anti- H. pylori potential of many plant and plant products and their 
usefulness for treatment of H. pylori infection has been studied. De et 
al. has mentioned the therapeutic potential of curcumin against H. 
pylori-associated gastroduodenal diseases and have shown 
eradication of H. pylori from the infected mouse stomach [26]. 
Similarly, our previous study has shown that ethanolic extract of 
Embilica officinalis can effectively treat H. pylori-associated gastric 
ulcer [27]. We have also found that methanolic extract of Paedra 
foetida was effective in inhibiting the growth of metronidazole-
resistant H. pylori strain in vitro [28]. In India, Parmelia is used in 
treating a number of diseases and as a food supplement which is 
mentioned in Indian Materia medica [29]. Previous studies showed 
its antimicrobial activity against different bacteria namely Clavibacter 
michiganensis, Pseudomonas solanacearum and fungi like Fusarium 
oxysporum and Rhizopus nigricans [29]. Antimicrobial properties of 
different lichens have also been tested against different pathogenic 
bacterial and fungal strains. Tippeswamy et al. used hot and cold 
extracts of the lichen in various solvents and tested them against the 
variety of bacterial and fungal pathogens [29]. Gulluce et al. found that 
methanolic extract of the lichen Parmelia saxatilis has stronger 
antibacterial property as compared to antifungal activity [30].  
We have included dual drug-resistant H. pylori strain in this study. 
Both the methanolic and ethanolic extracts of P. perlata were 
studied. In the present study, we found that methanolic and 
ethanolic extract of P. perlata potentially inhibited the growth of the 
H. pylori isolates in vitro that were isolated from the infected patient 
suffering from NERD and GERD. It is noteworthy that one of the H. 
pylori strain (HP1) was resistant to both clarithromycin and 
metronidazole and another strain (HP2) was resistant to 
metronidazole only which is the important component used in the 
first line therapy for the H. pylori treatment. So, our results suggest 
that methanolic and ethanolic extract of P. perlata acts through 
mechanisms distinctly different from the mode of action of these 
antibiotics for inhibition of H. pylori growth.  
Further research needs to be done to determine the compounds that 
are responsible for antibacterial activity against H. pylori. The 
findings also indicate that scientific studies carried out on medicinal 
plants having traditional claims of effectiveness [31, 32] can give 
fruitful results. 
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